1 / 17

American Society for Experimental Therapeutics Annual Meeting March 04-06, 2010 Therapeutic Development Resources at N

American Society for Experimental Therapeutics Annual Meeting March 04-06, 2010 Therapeutic Development Resources at NINDS . Bill Matthew Director, Office of Translational Research; NINDS bill.matthew@nih.gov. 1 -Matthew. Pipeline Principles: 101. Raw Material & Pump. Block Valve

sezja
Download Presentation

American Society for Experimental Therapeutics Annual Meeting March 04-06, 2010 Therapeutic Development Resources at N

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. American Society for Experimental TherapeuticsAnnual MeetingMarch 04-06, 2010 Therapeutic Development Resources at NINDS Bill MatthewDirector, Office of Translational Research; NINDS bill.matthew@nih.gov 1 -Matthew

  2. Pipeline Principles: 101 Raw Material & Pump Block Valve Station Final Delivery Basic Research Therapeutics 2 -Matthew

  3. T1 Translational Research: The process of using novel, basic research discoveries to develop clinical applications. bench T1 bedside T2 community 3 -Matthew

  4. NINDS Extramural Research Research Clusters Channels, Synapses & Circuits Systems & Cognitive Neuroscience Neural Environment Repair & Plasticity Neuro-degeneration Neuro- genetics Office of Translational Research Office of Clinical Research 4 -Matthew

  5. NINDS/OTR Activities in Therapeutic Development: Multiple ICs NINDS Basic Research -Target ID PreClincal Candidate – Safety/Tox Proof of Principle Lead Optimization First in Human Assay Screen for Hit Hit to Lead Anti-Convulsant Screening Program Exploratory/Developmental Projects in Translational Research Cooperative Program in Translational Research Translational SBIR Small Business Program: SBIR & STTR Spinal Muscular Atrophy Project Blueprint Neurotherapeutics Grand Challenge CounterACT Assay Development (Roadmap) Molecular Libraries (Roadmap) Small Molecule Optimization Drug Discovery for Nervous System Disorders RAID: Rapid Access to Interventional Development 5 -Matthew

  6. Anticonvulsant Screening Program (ASP) Goal: To facilitate the development of drugs for patients with epilepsy, resistant epilepsy and related CNS conditions Jim Stables js131e@nih.gov • Screening performed via a contract mechanism using a • battery of seizure models • Compounds are submitted by a broad base of Investigators: > 500 total • Industrial companies (~200) • Academic institutions (~300) • ASP Database > 29,000 small molecules – SAR chemistry & biology • Compounds in clinical development: currently six • Contributed to the development of ten marketed anti-convulsant drugs www.ninds.nih.gov/research/asp/index.htm 6 -Matthew

  7. Exploratory/Developmental Projects in Translational Research • Goal: Develop in vivo animal proof-of-concept for efficacy • Program (R21) primarily targets four tasks: • Creation and validation of screening assays • Development of animal models of disease • Identification of candidate therapeutics • Development of preliminary animal efficacy data • However, can be used for any preclinical development task Tom Miller tm208y@nih.gov www.ninds.nih.gov/research/translational/index.htm 7 -Matthew

  8. Cooperative Program inTranslational Research • Goal: Bring novel compounds and devices to the clinic • Cooperative Agreement, Milestone-driven program • Significant staff involvement • Reviewed by therapy development experts Tom Miller tm208y@nih.gov • IND/IDE by the end of the research project period • 6 filed INDs and 3 Clinical Trials www.ninds.nih.gov/research/translational/index.htm 8 -Matthew

  9. Cooperative Program inTranslational Research U44 Small Business Awards • Goal: Facilitate Small Business development of • neurotherapeutics • Fast-Track (Phase I & II) and Phase II Applications accepted • Phase I - identical scope as translational R21 • Phase II - identical scope as translational U01 Tom Miller tm208y@nih.gov For Translational Randy Stewart rs416y@nih.gov www.ninds.nih.gov/research/translational/index.htm 9 -Matthew

  10. THE SMA PROJECT Goal: Develop a safe and effective drug for Spinal Muscular Atrophy • Develop drugs that increase expression of SMN protein deficient in SMA patients • A ‘Virtual Pharma’ network of contracts for industry-style drug development: • medicinal chemistry • in vitro testing • pharmacological and toxicological studies • animal model testing • Industry-seasoned consultants and advisors to oversee programs Jill Heemskerk jh440o@nih.gov Coming Very Soon www.smaproject.org 10 -Matthew

  11. Blueprint Neurotherapeutics Grand Challenge • Goal: Provide Medicinal Chemistry and Pharm/tox expertise for developing new drugs for nervous system disorders • Investigator-initiated drug starting points • “Virtual Pharma” model of drug development • Provide access to industry-standard services: medicinal chemistry, pharm/tox, phase I clinical trials Jill Heemskerk jh440o@nih.gov Coming Very Soon • Provide industry expertise and guidance on committees • Develop licensing opportunities • Advance compounds through phase I trials • Investigator retains IP • Entry Requirements: - Hit compound(s) • - Primary screening assay • - Secondary assays for biological validation • www.grants.nih.gov/grants/guide/notice-files/NOT-NS-10-002.html 11 -Matthew

  12. CounterACT Countermeasures Against Chemical Threats Goal: To develop safe and effective therapies and diagnostic technologies for victims of emergency incidents involving exposure to highly toxic chemicals David Jett jettd@ninds.nih.gov • Research Centers of Excellence • Individual research projects at academic, government and industry laboratories • Cooperative Agreements, Milestone-driven • Efficacy screening and preclinical services contracts • Interagency Agreements with DoD laboratories www.ninds.nih.gov/counteract 12 -Matthew

  13. Assay Development: Molecular Libraries and Imaging Roadmap Program Goal: Develop assays to identify small molecule interactions via high-throughput screening of compound libraries, and to chemically optimize active compounds as molecular probes Mark Scheideler scheidererm@ninds.nih.gov www.ninds.nih.gov/research/molecular_libraries/index.htm 13 -Matthew

  14. NIH-RAIDNIH Rapid Access to Interventional Development • Pre-IND studies • All diseases • Access to government expertise and contract resources • Production, bulk supply, GMP manufacturing • Pharmacokinetic/ADME studies • IND-directed toxicology, and more • 6 successful IND submissions and 4 clinical trials to date Goal: To execute IND-enabling studies for extramural projects Tom Miller tm208y@nih.gov www.nihroadmap.nih.gov/raid 14 -Matthew

  15. Multiple ICs NINDS/OTR Activities in Therapeutic Development: NINDS Basic Research -Target ID PreClincal Candidate – Safety/Tox Proof of Principle Lead Optimization First in Human Assay Screen for Hit Hit to Lead Anti-Convulsant Screening Program Exploratory/Developmental Projects in Translational Research Cooperative Program in Translational Research Translational SBIR Small Business Program: SBIR & STTR Spinal Muscular Atrophy Project Blueprint Neurotherapeutics Grand Challenge CounterACT Assay Development (Roadmap) Molecular Libraries (Roadmap) Small Molecule Optimization Drug Discovery for Nervous System Disorders RAID: Rapid Access to Interventional Development 15 -Matthew

  16. Please Contact us… www.ninds.nih.gov Thank you 16 -Matthew

  17. grants.nih.gov/grants/funding/funding_program.htm

More Related